Scholarlink

<p>Advanced diagnostic technologies are driving precision medicine to revolutionize the field of hemato-oncology, that enable personalized treatments based on detailed molecular and genetic profiles. Innovations like next-generation sequencing, digital PCR, and liquid biopsies have reshaped diagnosis, classification, and treatment decisions in hematologic cancers such as leukemia, lymphoma, and myeloma. Each technology offers unique strengths NGS provides broad mutational insights, digital PCR enables ultra-sensitive measurable residual disease detection, and flow cytometry delivers rapid, accessible analysis while also facing specific limitations. This review explores how these tools collectively improve early detection, prognostication, and tailored therapy, enhancing patient outcomes. However, challenges persist, including tumor clonal diversity, microenvironmental influences, and unequal access due to cost and regulatory barriers. Future progress hinges on integrating multi-omics data, enhancing diagnostic accuracy, and expanding accessibility to fully harness personalized hemato-oncology, paving the way for more effective, individualized treatments and improved survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of advanced diagnostics on precision medicine in hemato oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Befikad Mandefro,
  • Dereje Mengesha Berta,
  • Amanuel kelem,
  • Bisrat Birke Teketelew,
  • Abateneh Melkamu,
  • Yalew Much,
  • Zewdu Mulatie,
  • Tiruneh Adane

摘要

Advanced diagnostic technologies are driving precision medicine to revolutionize the field of hemato-oncology, that enable personalized treatments based on detailed molecular and genetic profiles. Innovations like next-generation sequencing, digital PCR, and liquid biopsies have reshaped diagnosis, classification, and treatment decisions in hematologic cancers such as leukemia, lymphoma, and myeloma. Each technology offers unique strengths NGS provides broad mutational insights, digital PCR enables ultra-sensitive measurable residual disease detection, and flow cytometry delivers rapid, accessible analysis while also facing specific limitations. This review explores how these tools collectively improve early detection, prognostication, and tailored therapy, enhancing patient outcomes. However, challenges persist, including tumor clonal diversity, microenvironmental influences, and unequal access due to cost and regulatory barriers. Future progress hinges on integrating multi-omics data, enhancing diagnostic accuracy, and expanding accessibility to fully harness personalized hemato-oncology, paving the way for more effective, individualized treatments and improved survival.